Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

pembrolizumab 74Cyclophosphamide 50Cisplatin 46Nivolumab 36Radiotherapy 33Paclitaxel 33Carboplatin 31Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Vincristine 18Magnetic Resonance Spectroscopy 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Radiosurgery 17Surveys and Questionnaires 16Oxaliplatin 16Cytarabine 16Radiation 15Ipilimumab 15palbociclib 14durvalumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Histamine Antagonists × 90 days × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡